Main Article Content
Background. The current task of treating patients with type 2 diabetes mellitus and dyslipoproteinemia is the analysis of efficiency of the combination of standard hypoglycemic agents with phytotherapeutic drugs, but information about the feature of their use requires clarification. The purpose was to evaluate the influence of treatment with a fixed combination of gymnema, banaba leaves and bitter melon extract together with sulfonylurea and metformin on the dynamics of the clinical state, carbohydrate and lipid metabolism in patients with diabetes mellitus type 2. Materials and methods. The study involved 40 patients (16 men) aged 61.7 ± 7.8 years with type 2 diabetes. All patients before the treatment and after 2 months underwent: general blood test, evaluation of glycated hemoglobin, creatinine, urea, bilirubin, alanine aminotransferase, aspartate aminotransferase, cholesterol, high-density lipoproteins, low-density lipoproteins, triglyce-rides, glucose levels. All patients were divided into four groups according to the basic hypoglycemic therapy: group 1 received metformin (n = 6); group 2 — metformin and gliclazide (n = 10); group 3 — metformin and glimepiride (n = 14). The dose of hypoglycemic drugs was not changed during the whole study, Glucemedin was additionally administered in a dose of 1 capsule three times a day during 2 months. In group 4 (controls; n = 10), standard hypoglycemic therapy was not modified. Results. The inclusion of Glucemedin in the treatment resulted in a statistically significant decrease in the level of glycemia, glycated hemoglobin, triglycerides and an increase in high-density lipoproteins, and did not affect the concentration of total cholesterol and low-density lipoproteins. Conclusions. The obtained results demonstrated that the efficacy of combining standard hypoglycemic therapy with Glucemedin are consequent of the interacting impact of these pharmacological agents on the investigated parameters, which justifies the expediency of its use in the treatment of patients with type 2 diabetes mellitus.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our edition uses the copyright terms of Creative Commons for open access journals.
Authors, who are published in this journal, agree with the following terms:
- The authors retain rights for authorship of their article and grant to the edition the right of first publication of the article on a Creative Commons Attribution 4.0 International License, which allows others to freely distribute the published article, with the obligatory reference to the authors of original works and original publication in this journal.
- Directing the article for the publication to the editorial board (publisher), the author agrees with transmitting of rights for the protection and using the article, including parts of the article, which are protected by the copyrights, such as the author’s photo, pictures, charts, tables, etc., including the reproduction in the media and the Internet; for distributing; for the translation of the manuscript in all languages; for export and import of the publications copies of the writers’ article to spread, bringing to the general information.
- The rights mentioned above authors transfer to the edition (publisher) for the unlimited period of validity and on the territory of all countries of the world.
- The authors guarantee that they have exclusive rights for using of the article, which they have sent to the edition (publisher). The edition (the publisher) is not responsible for the violation of given guarantees by the authors to the third parties.
- The authors have the right to conclude separate supplement agreements that relate to non-exclusive distribution of their article in the form in which it had been published in the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.
- The policy of the journal permits and encourages the publication of the article in the Internet (in institutional repository or on a personal website) by the authors, because it contributes to productive scientific discussion and a positive effect on efficiency and dynamics of the citation of the article.
World Health Organization. The top 10 causes of death. Available from: http://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death. Accessed: May 24, 2018.
Lindström J, Ilanne-Parikka P, Peltonen M, et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet. 2006 Nov 11;368(9548):1673-9. doi: 10.1016/S0140-6736(06)69701-8.
Uma Makheswari M, Sudarsanam D. Phytomedicine for diabetes mellitus: an overview. Research in Pharmacy. 2011;1(4):28-37.
American Society of Hospital Pharmacists (ASHP). AHFS Drug information 2018. Authority of the Board of the American Society of Health-System Pharmacists, American Hospital Formulary Service. Bethesda, Md, USA; 2012. 3840 p.
Serghiyenko VA, Serghiyenko AA. Diabetychna kardiovaskuljarna avtonomna nejropatija: monografija [Diabetic cardiovascular autonomic neuropathy: monograph]. Lviv: Lviv National Medical University; 2016. 268 p. (in Ukrainian).
Valensi P. Cardiovascular autonomic neuropathy. In: McGuire DK, Marx N, editors. Diabetes in cardiovascular disease: A companion to braunworld’s heart disease. Amsterdam: Elsevier Saunders; 2015. 361-368 pp.
Kotseva K, Jennings C, De Bacquer D, De Backer G, Keil U, Wooda D. 1349 EUROASPIRE III: Lifestyle and risk factor management and use of drug therapies in coronary patients from 22 countries in Europe. Eur J Cardiovasc Nurs. 2008;7(1 Suppl):28. doi: 10.1016/J.EJCNURSE.2008.01.049.
Thakur GS, Sharma R, Sanodiya BS, Pandey M, Prasad GBKS and Bisen PS. Gymnema sylvestre: an alternative therapeutic agent for management of diabetes. Journal of Applied Pharmaceutical Science. 2012 Dec;2(12):1-6. doi: 10.7324/JAPS.2012.21201.
Ulbricht C, Abrams TR, Basch E, et al. An evidence-based systematic review of gymnema (Gymnema sylvestre R. Br.) by the Natural Standard Research Collaboration. J Diet Suppl. 2011 Sep;8(3):311-30. doi: 10.3109/19390211.2011.597977.
Miura T, Takagi S, Ishida T. Management of Diabetes and Its Complications with Banaba (Lagerstroemia speciosa L.) and Corosolic Acid. Evid Based Complement Alternat Med. 2012;2012:871495. doi: 10.1155/2012/871495.
Inayat U Rahman, Khan RU, Khalil Ur Rahman, Bashir M. Lower hypoglycemic but higher antiatherogenic effects of bitter melon than glibenclamide in type 2 diabetic patients. Nutr J. 2015 Jan 26;14:13. doi: 10.1186/1475-2891-14-13.